Elevation of Plasmin-α2-plasmin Inhibitor Complex Predicts the Diagnosis of Systemic AL Amyloidosis in Patients with Monoclonal Protein.
Ishiguro K et al. Intern Med. 2017 Oct 11. doi: 10.2169/internalmedicine.8999-17. [Epub ahead of print].

Metachronous solitary plasmacytoma.
Khosa R et al. BMJ Case Rep. 2017 Oct 19;2017. pii: bcr-2017-221780. doi: 10.1136/bcr-2017-221780.

Intratubular amyloid in light chain cast nephropathy is a risk factor for systemic light chain amyloidosis.
Gibier JB et al. Mod Pathol. 2017 Oct 20. doi: 10.1038/modpathol.2017.124. [Epub ahead of print].

Prognostic impact of immunoparesis at diagnosis and after treatment onset in patients with light-chain amyloidosis.
Rodríguez-Lobato LG et al. Amyloid. 2017 Oct 20:1-8. doi: 10.1080/13506129.2017.1390451. [Epub ahead of print].

Combination therapy incorporating Bcl-2 inhibition with Venetoclax for the treatment of refractory primary plasma cell leukemia with t (11;14).
Gonsalves WI et al. Eur J Haematol. 2017 Oct 24. doi: 10.1111/ejh.12986. [Epub ahead of print].